Vaginal Ecosystem and Network in the United States Study

NCT ID: NCT06472765

Last Updated: 2025-07-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

3250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-05-16

Study Completion Date

2028-05-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The central premise of this study is that the intricate balance and diversity of the vaginal microbiome plays a pivotal role in the onset, progression, and severity of various gynecological conditions. Specifically, the research aims to investigate how imbalances in microbial communities, such as the overgrowth of pathogenic bacteria or the depletion of beneficial ones, are linked to conditions like Bacterial Vaginosis, Candidiasis, Urinary Tract Infections, Vaginal Atrophy, and others. By employing PCR testing and the outcomes of next-generation sequencing (NGS) of the microbiome, the study seeks to identify distinct microbial profiles and patterns that are characteristic of each condition. This nuanced understanding is expected to lead to more accurate and early diagnosis, facilitating personalized and effective treatment strategies that go beyond the conventional, often indiscriminate use of antibiotics.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study protocol is developed to analyze the vaginal microbiome of women using a 56-panel PCR test and NGS test. The aim is to collect vaginal swab samples from a wide range of participants, including both healthy individuals and those with diagnosed gynecological conditions, to identify different microbiome profiles.

A key aspect of this study is the creation of a registry that will compile the data obtained from the PCR/NGS test results and participant information. This registry will serve as a valuable resource for ongoing research and will support the development of personalized approaches in women's health care. By systematically collecting and analyzing data, the registry will facilitate a better understanding of the vaginal microbiome's role in health and disease, aiding in the advancement of diagnostic and therapeutic strategies.

Additionally, the registry will provide a foundation for future studies, allowing for the exploration of long-term trends and relationships within the vaginal microbiome. This could lead to new insights into how the microbiome influences gynecological health and the development of targeted treatments. The combination of validating a precise diagnostic tool and establishing a comprehensive registry is aimed at enhancing patient care and supporting the broader research community in women's health.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bacterial Vaginosis Candidiasis Urinary Tract Infections Genitourinary Syndrome of Menopause Lichen Sclerosus Lichen Planus Vulvodynia Endometriosis Ureaplasma Infections Cancer Desquamative Inflammatory Vaginitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Premenopausal Healthy

Premenopausal Healthy

Vaginal Swab Collection

Intervention Type DIAGNOSTIC_TEST

Vaginal Swab Collection

Perimenopausal Healthy

Perimenopausal Healthy

Vaginal Swab Collection

Intervention Type DIAGNOSTIC_TEST

Vaginal Swab Collection

Postmenopausal Healthy

Postmenopausal Healthy

Vaginal Swab Collection

Intervention Type DIAGNOSTIC_TEST

Vaginal Swab Collection

Bacterial Vaginosis

Bacterial Vaginosis

Vaginal Swab Collection

Intervention Type DIAGNOSTIC_TEST

Vaginal Swab Collection

Candidiasis

Yeast Infections

Vaginal Swab Collection

Intervention Type DIAGNOSTIC_TEST

Vaginal Swab Collection

Urinary Tract Infection

Premenopausal and Postmenopausal Women

Vaginal Swab Collection

Intervention Type DIAGNOSTIC_TEST

Vaginal Swab Collection

Genitourinary Syndrome of Menopause

Vaginal Atrophy

Vaginal Swab Collection

Intervention Type DIAGNOSTIC_TEST

Vaginal Swab Collection

Lichen Sclerosus/Planus

Lichen Sclerosus/Planus

Vaginal Swab Collection

Intervention Type DIAGNOSTIC_TEST

Vaginal Swab Collection

Vulvodynia

Vulvodynia

Vaginal Swab Collection

Intervention Type DIAGNOSTIC_TEST

Vaginal Swab Collection

Endometriosis

Endometriosis

Vaginal Swab Collection

Intervention Type DIAGNOSTIC_TEST

Vaginal Swab Collection

Ureaplasma

Ureaplasma

Vaginal Swab Collection

Intervention Type DIAGNOSTIC_TEST

Vaginal Swab Collection

Desquamative Inflammatory Vaginitis (DIV)

Desquamative Inflammatory Vaginitis (DIV)

Vaginal Swab Collection

Intervention Type DIAGNOSTIC_TEST

Vaginal Swab Collection

Cancer

Group 1: Breast cancer patients diagnosed at stages 1-3, post-menopausal (due to surgical, chemical reasons, or age-related natural processes), and currently receiving anti-estrogen treatment for a minimum of 90 days.

Group 2: Breast cancer patients diagnosed at stages 1-3, pre-menopausal, and undergoing anti-estrogen endocrine therapy for at least 90 days.

Group 3: Participants diagnosed with any type of cancer at stages 1-3, not receiving anti-estrogen therapy, but have been using vaginal estrogen, prasterone, or DHEA for 90 days or more. Should not be on systemic hormone replacement therapy (estrogen with or without progesterone).

Group 4: Diagnosed with any type of cancer at stages 1-3, and should not be receiving any anti-estrogen therapy or using vaginal estrogen, prasterone, or DHEA. These individuals must not be on systemic hormone replacement therapy.

Group 5: Participants diagnosed at stage 4

Vaginal Swab Collection

Intervention Type DIAGNOSTIC_TEST

Vaginal Swab Collection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vaginal Swab Collection

Vaginal Swab Collection

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy cis-gender women between ages 18 and 89

Exclusion Criteria

* Pregnant or trying to conceive (i.e. IVF, IUI)
Minimum Eligible Age

18 Years

Maximum Eligible Age

89 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Vaginal Biome Science

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kimberly Capone, PhD

Role: PRINCIPAL_INVESTIGATOR

Vaginal Biome Science

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Women's Pelvic Health Center

Fullerton, California, United States

Site Status

Claris Health

Los Angeles, California, United States

Site Status

University of California Los Angeles Department of Radiation Oncology

Los Angeles, California, United States

Site Status

Pelvic Pain Rehab

Pasadena, California, United States

Site Status

Healthy Mothers, Healthy Babies Coalition of Hawaii

Honolulu, Hawaii, United States

Site Status

Rachel Rubin MD PLLC

Bethesda, Maryland, United States

Site Status

Dr. Christina Enzmann at Easton Advanced Aesthetics and Regenerative Medicine

Easton, Maryland, United States

Site Status

Empowered Midwifery and Wellness LLC

Alexandria, Minnesota, United States

Site Status

Xena Health

Henderson, Nevada, United States

Site Status

Empire OBGYN

Kenmore, New York, United States

Site Status

Gary H Goldman, MD

New York, New York, United States

Site Status

Camel City Women's Wellness

Winston-Salem, North Carolina, United States

Site Status

UH Hospitals

Mayfield Heights, Ohio, United States

Site Status

Northwest Obstetrics and Gynecology

Oklahoma City, Oklahoma, United States

Site Status

Haven Center for Sexual Medicine & Vulvovaginal Disorders

Tulsa, Oklahoma, United States

Site Status

Center of the Health

Corvallis, Oregon, United States

Site Status

Amber Wellness Group

Portland, Oregon, United States

Site Status

Center for Pelvic Medicine

Bryn Mawr, Pennsylvania, United States

Site Status

North Houston Gynecologic Oncology Surgeons, PLLC

Shenandoah, Texas, United States

Site Status

Hello Climax

Virginia Beach, Virginia, United States

Site Status

Integrative Naturopathic Medical Centre

Vancouver, British Columbia, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CRVA2024

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Improving Menstrual and VAginal Health for All
NCT06646185 NOT_YET_RECRUITING NA